<DOC>
	<DOCNO>NCT02158702</DOCNO>
	<brief_summary>Asian patient relapse myeloma prior treatment bortezomib lenalidomide treatment pomalidomde dexamethasone . Baseline , follow-up , survival toxicity information collect .</brief_summary>
	<brief_title>Efficacy Toxicity Study Pomalidomide Dexamethasone Patients Who Have Relapsed After Exposure Lenalidomide Bortezomib</brief_title>
	<detailed_description>Myeloma patient relapse prior treatment bortezomib lenalidomide survival le 1 year . Recently , randomize study Pomalidomide dexamethasone conduct compare placebo dexamethasone show pomalidomide improve survival group patient . Pomalidomide new immunomodulatory drug show active myeloma patient relapse bortezomib lenalidomide . A recent phase III study compare pomalidomide plus dexamethasone placebo plus high dose dexamethasone patient prior exposure bortezomib lenalidomide , show use pomalidomide significantly improve overall survival patient . However , study include Asian patient . Therefore efficacy toxicity pomalidomide remain described Asian patient</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Multiple myeloma , diagnose accord standard criterion , relapse refractory disease study entry 2 . Patients must evaluable multiple myeloma least one follow ( within 21 day start treatment ) 1 . Serum Mprotein ≥ 0.5g/dL , 2 . In subject without detectable serum Mprotein , Urine Mprotein ≥ 200mg/24 hour , serum free light chai ( sFLC ) &gt; 100mg/L ( involve light chain ) abnormal kappa/Lambda ratio 3 . Can receive 6 line prior treatment . ( Induction therapy follow stem cell transplantation consolidation/maintenance therapy consider one line treatment ) 4 . Must fail lenalidomide ( base 1 follow criterion : ) Refractory lenalidomide ; b ) well stable disease 3 cycle lenalidomide ) relapse previous treatment bortezomib . Refractoriness define disease progression treatment progression within 6 month last dose give therapy . Relapse define accord criterion IMWG 5 . Males females ≥ 18 year age &gt; country 's legal age adult consent 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 7 . Patients must meet follow clinical laboratory criterion 21 day start treatment : 1 . Absolute neutrophil count ( ANC ) ≥ 1,000/mm3 platelet ≥ 50,000/mm3 ( ≥ 30,000/mm3 myeloma involvement bone marrow &gt; 50 % ) 2 . Total bilirubin ≤ 1.5 x upper limit normal range ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 x ULN . 3 . Calculated creatinine clearance ≥ 45mL/min creatinine &lt; 3mg/dL . 8 . Female patient : 1 . Are naturally postmenopausal least 2 year enrolment 2 . Are surgically sterile 3 . If childbearing potential** , agree adhere pomalidomide pregnancy prevention risk management program Appendix 8 : All woman childbearing potential must agree two negative pregnancy test within 1014 day 24hrs commence pomalidomide use two reliable method contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start study ; 2 ) participate study ; 3 ) dose interruption ; 4 ) least 28 day study treatment discontinuation . The two method reliable contraception must include one highly effective method one additional effective method prevent pregnancy , plan conceive child within 6 month follow pomalidomide . ( See Appendix 8 Pregnancy Prevention Risk Management Program ) 9 . Male patient , even surgically sterilize ( i.e . status postvasectomy ) , : 1 . Agree practice effective barrier contraception entire study treatment period 28 day last dose study treatment , OR 2 . Agree completely abstain heterosexual intercourse , AND 3 . Must also adhere guideline pomalidomide pregnancy prevention risk management program 10 . Written inform consent accordance federal , local institutional guideline A female childbearing potential ( FCBP ) define sexually mature woman : 1 undergone hysterectomy bilateral oophorectomy 2 , naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( I.E , menses time precede 24 consecutive month ) . 1.1 . Exclusion Criteria 1 . Female patient lactate pregnant 2 . Multiple Myeloma IgM subtype 3 . Glucocorticoid therapy ( prednisolone &gt; 30mg/day equivalent ) within 14 day prior informed consent obtain 4 . POEMS syndrome 5 . Plasma cell leukemia circulate plasma cell ≥ 2 x 109/L 6 . Waldenstrom 's Macroglobulinaemia 7 . Patients know amyloidosis 8 . Chemotherapy approve investigation anticancer therapeutic within 21 day prior start pomalidomide treatment 9 . Focal radiation therapy within 7 day prior start pomalidomide . Radiation therapy extend field involve significant volume bone marrow within 21 day prior start pomalidomide 10 . Immunotherapy ( exclude steroid ) 21 day prior start pomalidomide 11 . Major surgery ( exclude kyphoplasty ) within 28 day prior start pomalidomide 12 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischaemia , conduction abnormality uncontrolled conventional intervention . Myocardial infarction within 4 month prior inform consent obtain 13 . Known HIV seropositive , hepatitis C infection , and/or hepatitis B ( except patient hepatitis B surface antigen core antibody receive respond antiviral therapy direct hepatitis B : patient allow ) 14 . Patients know cirrhosis 15 . Second malignancy within past 3 year except : 1 . Adequately treat basal cell squamous cell skin cancer 2 . Carcinoma situ cervix 3 . Breast carcinoma situ full surgical resection 16 . Patients myelodysplastic syndrome 17 . Patients steroid lenalidomide hypersensitivity 18 . Prior treatment pomalidomide 19 . Ongoing graftversushost disease 20 . Patients pleural effusion require thoracentesis ascites require paracentesis within 14 day prior start pomalidomide treatment 21 . Contraindication require concomitant drug supportive treatment 22 . Any clinically significant medical disease psychiatric condition , investigator 's opinion , may interfere protocol adherence patient 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Relapsed Myeloma Patients</keyword>
	<keyword>Relapsed use Bortezomib Lenalidomide</keyword>
	<keyword>Pomalidomide Dexamethasone</keyword>
	<keyword>Efficacy Safety</keyword>
</DOC>